Screener Summaries Updates Institutions Sign In More Updates › Other Events › QTTB Other Events · Jul 13, 2026
Q32 Bio Inc. announced topline results from Part B of the SIGNAL-AA Phase 2a clinical trial evaluating bempikibart… QTTB Q32 Bio Inc.
Q32 Bio Inc. announced topline results from Part B of the SIGNAL-AA Phase 2a clinical trial evaluating bempikibart (ADX-914) in patients with alopecia areata. The company used a presentation to communicate these findings. Q32 Bio Inc. is a biotechnology company focused on developing medical treatments for autoimmune diseases.
More from Q32 Bio Inc. Q32 Bio reports Q3 net loss of $8.9M, holds $289.6M cash as it prepares for Phase 3 trials Nov 4, 2026 Q32 Bio Inc. reported financial results for the quarter ended June 30, 2026, alongside a corporate update on its… Aug 5, 2026 Q32 Bio Inc. entered into an underwriting agreement on July 14, 2026, to issue and sell 6,027,399 shares of common… Jul 15, 2026 Q32 Bio Inc. announced positive 36-week topline results from Part B of the SIGNAL-AA Phase 2a clinical trial for… Jul 13, 2026 All content on this site is for informational purposes only and does not constitute financial, investment, legal, or tax advice. Past performance is not indicative of future results. Always consult a qualified financial advisor before making investment decisions.
Financial data is obtained from public filings and third-party providers and is provided “as-is” without any guarantee of accuracy, completeness, or timeliness.
© 2026 go-intrinsic.com. All rights reserved.
